NASDAQ$XXII

22nd Century Group Inc. · Q1 2022 earnings

Q1 2022 earnings · · Investor relations

Briefing

Announced first quarter 2022 financial results, highlighted by a 33% increase in net sales year-over-year and the launch of VLN® pilot program in Chicago.

22nd Century Group reported a 33% increase in net sales for the first quarter of 2022, reaching $9.0 million. The company launched its VLN® pilot program in Chicago with Circle K and began VLN® shipments to South Korea for its first international launch.

  • Launched VLN® Pilot Program in Chicago with Circle K as First Retail Trade Partner.
  • Began VLN® Shipments to South Korea for First International Launch.
  • FDA’s Proposed Menthol Ban Could Leave VLN® Menthol King as the Only Menthol Cigarette on the Market.
  • Achieved Breakthrough in Hemp/Cannabis Plant Transformation Technology.

Headline financials

Total Revenue

$9.05M

Previous: $6.81M+32.9%
EPS (adj)

-$12.00

Previous: -$7.20-66.7%
Capital Expenditures

-$258K

Previous: -$100K-158.0%
Free Cash Flow

-$9.18M

Previous: -$5.13M-78.9%
Net Income

-$8.92M

Previous: -$5.03M-77.3%
Operating Income

-$8.15M

Previous: -$5.17M-57.5%
Gross Profit

-$8.59M

Previous: -$6.16M-39.4%
Cash & Equivalents

$1.58M

Previous: $30.9M-94.9%
Total Assets

$66.5M

Previous: $59.7M+11.4%
Stock-Based Comp

$1.21M

Previous: $507K+139.3%

Revenue & EPS history

22nd Century Group · Revenue · Quarterly

$9.05M

Q1 2022+32.9%vs Q1 2021
Beat estimate in 6 of 12 quarters(50%)
ActualEstimate

Forward guidance

The company is focused on expanding VLN® marketing and distribution, securing regulatory clearances, and pursuing partnerships for VLN® tobacco and IP across multiple countries.

Tailwinds

  • Continuing to explore launch opportunities in additional markets in Asia and Europe with limited regulatory barriers while also leveraging VLN®’s MRTP authorization from FDA toward seeking approval in markets with higher regulatory barriers.
  • 22nd Century Group continued its support of FDA’s proposed ban on menthol as a characterizing flavor in conventional nicotine cigarettes.
  • FDA’s proposed menthol cigarette ban could leave VLN® Menthol King as the only combustible menthol cigarette on the market, providing a critical off-ramp to help current menthol smokers to smoke less.
  • Completing delivery of a purchase order for 3 million additional variable nicotine research cigarettes, including menthol, for use in studies underpinning FDA’s proposed menthol ban and reduced nicotine content proposals.
  • Contracted the largest VLN® tobacco planting to date to support expansion in both the U.S. and international markets.

Historical earnings impact

How earnings announcements have historically affected this stock's price.

Avg. return before/after earnings

Based on 18 quarterly earnings reports · overlaid with Q1 2022

Historical avgQ1 2022

-2.9%

Avg return

Earnings day

-3.9%

Avg return

5 days after

-7.7%

Avg return

30 days after

32%

19 / 59 earnings

Positive

+37.4%

Q4 2020

Best reaction

-25.8%

Q2 2023

Worst reaction

Earnings price reactions
QuarterReport dateReaction (Day 0)+5 days+30 days
Q4 2025-2.2%-13.2%
Q1 2026-16.6%-33.2%-44.0%
Q3 2025-17.0%-20.0%-32.3%
Q1 2025+1.9%-18.7%-59.3%
Q4 2024-2.6%-12.6%-59.2%
Q3 2024-3.0%-10.7%-28.2%
Q2 2024-14.9%-21.9%-62.8%
Q1 2024-1.9%-9.7%-47.9%
Q4 2023-8.7%-7.7%-18.1%
Q3 2023-15.2%-19.0%-52.5%
Q2 2023-25.8%-23.3%-51.6%
Q1 2023-5.0%-13.8%-16.1%
Q4 2022-0.7%-4.9%-17.9%
Q3 2022-21.0%-13.8%-26.1%
Q2 2022-10.7%-11.2%-32.7%
Q1 2022-8.3%-20.3%-3.1%
Q4 2021-2.1%-9.8%-0.9%
Q3 2021-0.7%+1.7%-22.1%
Q2 2021+18.1%+26.4%+12.4%
Q1 2021+8.4%+10.7%+14.9%
Q4 2020+37.4%+27.0%+62.6%
Q3 2020+13.2%+12.5%+129.0%
Q2 2020-2.1%-4.6%-19.3%
Q1 2020-3.6%-9.9%-7.7%
Q4 2019-5.8%+2.2%-7.7%
Q3 2019-3.6%-10.2%-40.8%
Q2 2019+3.1%+18.9%+31.4%
Q1 2019-11.4%-18.6%-18.1%
Q4 2018+1.6%+7.0%+1.1%
Q3 2018+3.1%+0.8%+9.8%
Q2 2018-1.6%+2.8%+2.4%
Q1 2018+6.8%+23.2%+7.7%
Q4 2017+11.3%+5.8%-10.1%
Q3 2017+0.0%+5.8%+28.6%
Q2 2017-7.9%-10.5%+4.6%
Q1 2017+6.9%+6.9%+40.5%
Q4 2016+0.5%+3.7%+44.4%
Q3 2016+0.8%-0.8%-21.2%
Q2 2016+2.2%+10.9%+17.4%
Q1 2016+2.6%
Q4 2015-4.8%
Q3 2015-9.3%
Q2 2015-7.0%
Q1 2015+21.5%
Q4 2014-16.5%
Q4 2013-16.5%
Q3 2014-9.2%
Q2 2014-1.4%
Q1 2014-2.9%
Q3 2013+4.2%
Q2 2013-18.5%
Q1 2013+0.0%
Q4 2012-9.1%
Q3 2012-20.0%
Q2 2012-7.1%
Q1 2012+1.5%
Q4 2011+1.5%
Q3 2011+0.0%
Q2 2011+0.0%
Q4 2010
Q3 2010
Q2 2010
Q1 2010

Discussion

Share your read of this quarter. Sign-in carries your eToro identity.

Join the conversation

Sign in with eToro to post your read of this quarter and vote on others'.

Sign in with eToro